CAS: 151096-09-2 Moxifloxacin Powder API Powder

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: HNB-Moxifloxacin
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Adult
• State: Powder
• Purity: >99%
• Molecular Weight: 401.43
• Molecular Formula: C21h24fn3o4
• Density: 1.4+0.1 g/cm3
• Assay: HPLC99%
• Sample: 10g Available
• Factory Supply: Yes
• Appearance: White Powder
• Usage: Animal Pharmaceuticals
• Shelf Life: 2 Years Proper Storage
• Certificate: GMP/ISO9001
• Product Name: Moxifloxacin
• Packing: Carton Box or Drum
• CAS: 151096-09-2
• Function: Antibiotic
• Payment: Tt/Western Union
• Transport Package: Carton Box
• Specification: Moxifloxacin 99%
• Trademark: HNB
• Origin: China
• HS Code: 3006920000
• Production Capacity: 1000kg Per Month

Product Description

product name	Moxifloxacin
cas number	151096-09-2
apperance	white powder
Density	1.4±0.1 g/cm3
MF	C21H24FN3O4
MW	401.43

English alias: 4-dihydroquinoline-3-carboxylic acid
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,
Molecular formula: C21H24FN3O4
Molecular weight: 401.4314
CAS Number: 151096-09-2

Physical and chemical properties
Appearance and properties: almost white crystalline powder
Density: 1.408 g/cm3
Melting point: 193-195 °C(lit.)
Boiling point: 636.4ºC at 760 mmHg
Flash point: 338.7ºC
Refractive index: 1.633
Vapor pressure: 4.56E-17mmHg at 25°C [3]
Security Information
Customs code: 29329970
WGK Germany: 3
Hazard category code: R 22
Safety instructions: S26-S37/39
Dangerous goods mark: Xn

Moxifloxacin is a synthetic quinolone antibacterial drug, which is a relatively new type of synthetic antibacterial drug. It has the advantages of strong antibacterial activity, broad antibacterial spectrum, resistance to resistance and effectiveness for common drug-resistant bacteria, long half-life, and few adverse reactions.
Treat adults with upper and lower respiratory tract infections. Such as acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, and skin and soft tissue infections.